In yesterday’s Wall Street session, Cybin Inc. (AMEX:CYBN) shares traded at $0.41, up 1.49% from the previous session.
6 analysts cover Cybin Inc. (AMEX:CYBN), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $1.13, we find $3.75. Given the previous closing price of $0.40, this indicates a potential upside of 837.5 percent. CYBN stock price is now 22.66% away from the 50-day moving average and 3.98% away from the 200-day moving average. The market capitalization of the company currently stands at $99.47M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 6. Brokers who have rated the stock have averaged $4.48 as their price target over the next twelve months.
A total of 22.29% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CYBN stock. A new stake in Cybin Inc. shares was purchased by SIMPLIFY ASSET MANAGEMENT INC. during the first quarter worth $205,000. FNY INVESTMENT ADVISERS, LLC invested $57,000 in shares of CYBN during the first quarter. In the first quarter, BARCLAYS PLC acquired a new stake in Cybin Inc. valued at approximately $25,000. WALLED LAKE PLANNING & WEALTH MANAGEMENT, LLC acquired a new stake in CYBN for approximately $24,000. EVOKE WEALTH, LLC purchased a new stake in CYBN valued at around $10,000 in the second quarter. In total, there are 75 active investors with 7.86% ownership of the company’s stock.
On Tuesday morning Cybin Inc. (AMEX: CYBN) stock kicked off with the opening price of $0.4050. During the past 12 months, Cybin Inc. has had a low of $0.21 and a high of $1.14. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.10, and a quick ratio of 4.10. The fifty day moving average price for CYBN is $0.3343 and a two-hundred day moving average price translates $0.3943 for the stock.
The latest earnings results from Cybin Inc. (AMEX: CYBN) was released for Mar, 2023.
Cybin Inc.(CYBN) Company Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
